Loading clinical trials...
Loading clinical trials...
A Multi-center Randomized Clinical Study Comparing Reduced-dose (35mg/kg) Versus Standard Dose (50mg/kg) Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin (ATG) and Tacrolimus and Post-engraftment Anti-thymoglobin as Graft Versus Host Disease (GVHD) Prophylaxis in Patients Undergo Alternative Donor Peripheral Hematopoietic Stem Cell Transplantation
Conditions
Interventions
reduced-dose PTCy
Standard dose PTCY
Locations
1
China
Ruijin hsopital
Shanghai, Shanghai Municipality, China
Start Date
January 1, 2025
Primary Completion Date
December 1, 2027
Completion Date
July 1, 2028
Last Updated
March 17, 2026
NCT01804686
NCT03394365
NCT07356245
NCT04660487
NCT04745221
NCT06271616
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions